

15101838D

HOUSE BILL NO. 1737

Offered January 14, 2015

Prefiled January 12, 2015

A BILL to amend and reenact §§ 54.1-3401, 54.1-3406, 54.1-3410.2, and 54.1-3434.4 of the Code of Virginia and to amend the Code of Virginia by adding in Article 2 of Chapter 34 of Title 54.1 a section numbered 54.1-3434.05 and by adding in Article 2.1 of Chapter 34 of Title 54.1 a section numbered 54.1-3434.5, relating to outsourcing facilities and nonresident outsourcing facilities and compounding for office-based administration.

Patron—Hodges

Referred to Committee on Health, Welfare and Institutions

Be it enacted by the General Assembly of Virginia:

1. That §§ 54.1-3401, 54.1-3406, 54.1-3410.2, and 54.1-3434.4 of the Code of Virginia are amended and reenacted and that the Code of Virginia is amended by adding in Article 2 of Chapter 34 of Title 54.1 a section numbered 54.1-3434.05 and by adding in Article 2.1 of Chapter 34 of Title 54.1 a section numbered 54.1-3434.5 as follows:

§ 54.1-3401. Definitions.

As used in this chapter, unless the context requires a different meaning:

"Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of a patient or research subject by (i) a practitioner or by his authorized agent and under his direction or (ii) the patient or research subject at the direction and in the presence of the practitioner.

"Advertisement" means all representations disseminated in any manner or by any means, other than by labeling, for the purpose of inducing, or which are likely to induce, directly or indirectly, the purchase of drugs or devices.

"Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. It does not include a common or contract carrier, public warehouseman, or employee of the carrier or warehouseman.

"Anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related to testosterone, other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone.

"Animal" means any nonhuman animate being endowed with the power of voluntary action.

"Automated drug dispensing system" means a mechanical or electronic system that performs operations or activities, other than compounding or administration, relating to pharmacy services, including the storage, dispensing, or distribution of drugs and the collection, control, and maintenance of all transaction information, to provide security and accountability for such drugs.

"Biological product" means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

"Biosimilar" means a biological product that is highly similar to a specific reference biological product, notwithstanding minor differences in clinically inactive compounds, such that there are no clinically meaningful differences between the reference biological product and the biological product that has been licensed as a biosimilar pursuant to 42 U.S.C. § 262(k) in terms of safety, purity, and potency of the product.

"Board" means the Board of Pharmacy.

"Bulk drug substance" means any substance that is represented for use, and that, when used in the compounding, manufacturing, processing, or packaging of a drug, becomes an active ingredient or a finished dosage form of the drug; however, "bulk drug substance" shall not include intermediates that are used in the synthesis of such substances.

"Change of ownership" of an existing entity permitted, registered, or licensed by the Board means (i) the sale or transfer of all or substantially all of the assets of the entity or of any corporation that owns or controls the entity; (ii) the creation of a partnership by a sole proprietor, the dissolution of a partnership, or change in partnership composition; (iii) the acquisition or disposal of 50 percent or more of the outstanding shares of voting stock of a corporation owning the entity or of the parent corporation of a wholly owned subsidiary owning the entity, except that this shall not apply to any corporation the voting stock of which is actively traded on any securities exchange or in any over-the-counter market;

59 (iv) the merger of a corporation owning the entity or of the parent corporation of a wholly-owned
60 subsidiary owning the entity with another business or corporation; or (v) the expiration or forfeiture of a
61 corporation's charter.

62 "Compounding" means the combining of two or more ingredients to fabricate such ingredients into a
63 single preparation and includes the mixing, assembling, packaging, or labeling of a drug or device (i) by
64 a pharmacist, or within a permitted pharmacy, pursuant to a valid prescription issued for a medicinal or
65 therapeutic purpose in the context of a bona fide practitioner-patient-pharmacist relationship, or in
66 expectation of receiving a valid prescription based on observed historical patterns of prescribing and
67 dispensing; (ii) by a practitioner of medicine, osteopathy, podiatry, dentistry, or veterinary medicine as
68 an incident to his administering or dispensing, if authorized to dispense, a controlled substance in the
69 course of his professional practice; or (iii) for the purpose of, or as incident to, research, teaching, or
70 chemical analysis and not for sale or for dispensing. The mixing, diluting, or reconstituting of a
71 manufacturer's product drugs for the purpose of administration to a patient, when performed by a
72 practitioner of medicine or osteopathy licensed under Chapter 29 (§ 54.1-2900 et seq.), a person
73 supervised by such practitioner pursuant to subdivision A 6 or A 19 of § 54.1-2901, or a person
74 supervised by such practitioner or a licensed nurse practitioner or physician assistant pursuant to
75 subdivision A 4 of § 54.1-2901 shall not be considered compounding.

76 "Controlled substance" means a drug, substance, or immediate precursor in Schedules I through VI of
77 this chapter. The term shall not include distilled spirits, wine, malt beverages, or tobacco as those terms
78 are defined or used in Title 3.2 or Title 4.1. The term "controlled substance" includes a controlled
79 substance analog that has been placed into Schedule I or II by the Board pursuant to the regulatory
80 authority in subsection D of § 54.1-3443.

81 "Controlled substance analog" means a substance the chemical structure of which is substantially
82 similar to the chemical structure of a controlled substance in Schedule I or II and either (i) which has a
83 stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar
84 to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a
85 controlled substance in Schedule I or II or (ii) with respect to a particular person, which such person
86 represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous
87 system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect
88 on the central nervous system of a controlled substance in Schedule I or II. "Controlled substance
89 analog" does not include (a) any substance for which there is an approved new drug application as
90 defined under § 505 of the federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355) or that is generally
91 recognized as safe and effective pursuant to §§ 501, 502, and 503 of the federal Food, Drug, and
92 Cosmetic Act (21 U.S.C. §§ 351, 352, and 353) and 21 C.F.R. Part 330; (b) with respect to a particular
93 person, any substance for which an exemption is in effect for investigational use for that person under
94 § 505 of the federal Food, Drug, and Cosmetic Act to the extent that the conduct with respect to that
95 substance is pursuant to such exemption; or (c) any substance to the extent not intended for human
96 consumption before such an exemption takes effect with respect to that substance.

97 "DEA" means the Drug Enforcement Administration, U.S. Department of Justice, or its successor
98 agency.

99 "Deliver" or "delivery" means the actual, constructive, or attempted transfer of any item regulated by
100 this chapter, whether or not there exists an agency relationship.

101 "Device" means instruments, apparatus, and contrivances, including their components, parts, and
102 accessories, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in
103 man or animals or to affect the structure or any function of the body of man or animals.

104 "Dialysis care technician" or "dialysis patient care technician" means an individual who is certified
105 by an organization approved by the Board of Health Professions pursuant to Chapter 27.01
106 (§ 54.1-2729.1 et seq.) and who, under the supervision of a licensed physician, nurse practitioner,
107 physician assistant, or a registered nurse, assists in the care of patients undergoing renal dialysis
108 treatments in a Medicare-certified renal dialysis facility.

109 "Dialysis solution" means either the commercially available, unopened, sterile solutions whose
110 purpose is to be instilled into the peritoneal cavity during the medical procedure known as peritoneal
111 dialysis, or commercially available solutions whose purpose is to be used in the performance of
112 hemodialysis not to include any solutions administered to the patient intravenously.

113 "Dispense" means to deliver a drug to an ultimate user or research subject by or pursuant to the
114 lawful order of a practitioner, including the prescribing and administering, packaging, labeling, or
115 compounding necessary to prepare the substance for that delivery. However, dispensing shall not include
116 the transportation of drugs mixed, diluted, or reconstituted in accordance with this chapter to other sites
117 operated by such practitioner or that practitioner's medical practice for the purpose of administration of
118 such drugs to patients of the practitioner or that practitioner's medical practice at such other sites. For
119 practitioners of medicine or osteopathy, "dispense" shall only include the provision of drugs by a
120 practitioner to patients to take with them away from the practitioner's place of practice.

"Dispenser" means a practitioner who dispenses.

"Distribute" means to deliver other than by administering or dispensing a controlled substance.

"Distributor" means a person who distributes.

"Drug" means (i) articles or substances recognized in the official United States Pharmacopoeia National Formulary or official Homeopathic Pharmacopoeia of the United States, or any supplement to any of them; (ii) articles or substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or animals; (iii) articles or substances, other than food, intended to affect the structure or any function of the body of man or animals; (iv) articles or substances intended for use as a component of any article specified in clause (i), (ii), or (iii); or (v) a biological product. "Drug" does not include devices or their components, parts, or accessories.

"Drug product" means a specific drug in dosage form from a known source of manufacture, whether by brand or therapeutically equivalent drug product name.

"Electronic transmission prescription" means any prescription, other than an oral or written prescription or a prescription transmitted by facsimile machine, that is electronically transmitted directly to a pharmacy without interception or intervention from a third party from a practitioner authorized to prescribe or from one pharmacy to another pharmacy.

"Facsimile (FAX) prescription" means a written prescription or order that is transmitted by an electronic device over telephone lines that sends the exact image to the receiving pharmacy in hard copy form.

"FDA" means the U.S. Food and Drug Administration.

"Hashish oil" means any oily extract containing one or more cannabinoids, but shall not include any such extract with a tetrahydrocannabinol content of less than 12 percent by weight.

"Immediate precursor" means a substance which the Board of Pharmacy has found to be and by regulation designates as being the principal compound commonly used or produced primarily for use, and which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail, or limit manufacture.

"Interchangeable" means a biosimilar that meets safety standards for determining interchangeability pursuant to 42 U.S.C. § 262(k)(4).

"Label" means a display of written, printed, or graphic matter upon the immediate container of any article. A requirement made by or under authority of this chapter that any word, statement, or other information appear on the label shall not be considered to be complied with unless such word, statement, or other information also appears on the outside container or wrapper, if any, of the retail package of such article or is easily legible through the outside container or wrapper.

"Labeling" means all labels and other written, printed, or graphic matter on an article or any of its containers or wrappers, or accompanying such article.

"Manufacture" means the production, preparation, propagation, conversion, or processing of any item regulated by this chapter, either directly or indirectly by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its container. This term does not include compounding.

"Manufacturer" means every person who manufactures.

"Marijuana" means any part of a plant of the genus Cannabis whether growing or not, its seeds, or its resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds, or its resin. Marijuana shall not include any oily extract containing one or more cannabinoids unless such extract contains less than 12 percent of tetrahydrocannabinol by weight, nor shall marijuana include the mature stalks of such plant, fiber produced from such stalk, or oil or cake made from the seeds of such plant, unless such stalks, fiber, oil, or cake is combined with other parts of plants of the genus Cannabis.

"Medical equipment supplier" means any person, as defined in § 1-230, engaged in the delivery to the ultimate consumer, pursuant to the lawful order of a practitioner, of hypodermic syringes and needles, medicinal oxygen, Schedule VI controlled devices, those Schedule VI controlled substances with no medicinal properties that are used for the operation and cleaning of medical equipment, solutions for peritoneal dialysis, and sterile water or saline for irrigation.

"Narcotic drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (i) opium, opiates, and any salt, compound, derivative, or preparation of opium or opiates; (ii) any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in clause (i), but not including the isoquinoline alkaloids of opium; (iii) opium poppy and poppy straw; (iv) coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of these

182 substances, but not including decocainized coca leaves or extraction of coca leaves which do not contain
183 cocaine or ecgonine.

184 "New drug" means (i) any drug, except a new animal drug or an animal feed bearing or containing a
185 new animal drug, the composition of which is such that such drug is not generally recognized, among
186 experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs,
187 as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling,
188 except that such a drug not so recognized shall not be deemed to be a "new drug" if at any time prior
189 to the enactment of this chapter it was subject to the Food and Drugs Act of June 30, 1906, as
190 amended, and if at such time its labeling contained the same representations concerning the conditions
191 of its use, or (ii) any drug, except a new animal drug or an animal feed bearing or containing a new
192 animal drug, the composition of which is such that such drug, as a result of investigations to determine
193 its safety and effectiveness for use under such conditions, has become so recognized, but which has not,
194 otherwise than in such investigations, been used to a material extent or for a material time under such
195 conditions.

196 "Nuclear medicine technologist" means an individual who holds a current certification with the
197 American Registry of Radiological Technologists or the Nuclear Medicine Technology Certification
198 Board.

199 "Official compendium" means the official United States Pharmacopoeia National Formulary, official
200 Homeopathic Pharmacopoeia of the United States, or any supplement to any of them.

201 "Official written order" means an order written on a form provided for that purpose by the U.S. Drug
202 Enforcement Administration, under any laws of the United States making provision therefor, if such
203 order forms are authorized and required by federal law, and if no such order form is provided then on
204 an official form provided for that purpose by the Board of Pharmacy.

205 "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to
206 morphine or being capable of conversion into a drug having such addiction-forming or
207 addiction-sustaining liability. It does not include, unless specifically designated as controlled under
208 Article 4 (§ 54.1-3437 et seq.), the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts
209 (dextromethorphan). It does include its racemic and levorotatory forms.

210 "Opium poppy" means the plant of the species *Papaver somniferum* L., except the seeds thereof.

211 "Original package" means the unbroken container or wrapping in which any drug or medicine is
212 enclosed together with label and labeling, put up by or for the manufacturer, wholesaler, or distributor
213 for use in the delivery or display of such article.

214 *"Outsourcing facility" means a facility that is engaged in the compounding of sterile drugs and is*
215 *currently registered as an outsourcing facility with the U.S. Secretary of Health and Human Services*
216 *and that complies with all applicable requirements of federal and state law, including the Federal Food,*
217 *Drug, and Cosmetic Act.*

218 "Person" means both the plural and singular, as the case demands, and includes an individual,
219 partnership, corporation, association, governmental agency, trust, or other institution or entity.

220 "Pharmacist-in-charge" means the person who, being licensed as a pharmacist, signs the application
221 for a pharmacy permit and assumes full legal responsibility for the operation of the relevant pharmacy in
222 a manner complying with the laws and regulations for the practice of pharmacy and the sale and
223 dispensing of controlled substances; the "pharmacist-in-charge" shall personally supervise the pharmacy
224 and the pharmacy's personnel as required by § 54.1-3432.

225 "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

226 "Practitioner" means a physician, dentist, licensed nurse practitioner pursuant to § 54.1-2957.01,
227 licensed physician assistant pursuant to § 54.1-2952.1, pharmacist pursuant to § 54.1-3300, TPA-certified
228 optometrist pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32, veterinarian, scientific investigator,
229 or other person licensed, registered, or otherwise permitted to distribute, dispense, prescribe and
230 administer, or conduct research with respect to a controlled substance in the course of professional
231 practice or research in the Commonwealth.

232 "Prescriber" means a practitioner who is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue
233 a prescription.

234 "Prescription" means an order for drugs or medical supplies, written or signed or transmitted by word
235 of mouth, telephone, telegraph, or other means of communication to a pharmacist by a duly licensed
236 physician, dentist, veterinarian, or other practitioner authorized by law to prescribe and administer such
237 drugs or medical supplies.

238 "Prescription drug" means any drug required by federal law or regulation to be dispensed only
239 pursuant to a prescription, including finished dosage forms and active ingredients subject to § 503(b) of
240 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353(b)).

241 "Production" or "produce" includes the manufacture, planting, cultivation, growing, or harvesting of
242 a controlled substance or marijuana.

243 "Proprietary medicine" means a completely compounded nonprescription drug in its unbroken,

original package which does not contain any controlled substance or marijuana as defined in this chapter and is not in itself poisonous, and which is sold, offered, promoted, or advertised directly to the general public by or under the authority of the manufacturer or primary distributor, under a trademark, trade name, or other trade symbol privately owned, and the labeling of which conforms to the requirements of this chapter and applicable federal law. However, this definition shall not include a drug that is only advertised or promoted professionally to licensed practitioners, a narcotic or drug containing a narcotic, a drug that may be dispensed only upon prescription or the label of which bears substantially the statement "Warning - may be habit-forming," or a drug intended for injection.

"Radiopharmaceutical" means any drug that exhibits spontaneous disintegration of unstable nuclei with the emission of nuclear particles or photons and includes any non-radioactive reagent kit or radionuclide generator that is intended to be used in the preparation of any such substance, but does not include drugs such as carbon-containing compounds or potassium-containing salts that include trace quantities of naturally occurring radionuclides. The term also includes any biological product that is labeled with a radionuclide or intended solely to be labeled with a radionuclide.

"Reference biological product" means the single biological product licensed pursuant to 42 U.S.C. § 262(a) against which a biological product is evaluated in an application submitted to the U.S. Food and Drug Administration for licensure of biological products as biosimilar or interchangeable pursuant to 42 U.S.C. § 262(k).

"Sale" includes barter, exchange, or gift, or offer therefor, and each such transaction made by any person, whether as an individual, proprietor, agent, servant, or employee.

"Therapeutically equivalent drug products" means drug products that contain the same active ingredients and are identical in strength or concentration, dosage form, and route of administration and that are classified as being therapeutically equivalent by the U.S. Food and Drug Administration pursuant to the definition of "therapeutically equivalent drug products" set forth in the most recent edition of the Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as the "Orange Book."

"USP-NF" means the current edition of the United States Pharmacopeia-National Formulary.

"Warehouser" means any person, other than a wholesale distributor, engaged in the business of selling or otherwise distributing prescription drugs or devices to any person who is not the ultimate user or consumer. No person shall be subject to any state or local tax by reason of this definition.

"Wholesale distribution" means distribution of prescription drugs to persons other than consumers or patients, subject to the exceptions set forth in § 54.1-3401.1.

"Wholesale distributor" means any person engaged in wholesale distribution of prescription drugs including, but not limited to, manufacturers; repackers; own-label distributors; private-label distributors; jobbers; brokers; warehouses, including manufacturers' and distributors' warehouses, chain drug warehouses conducting wholesale distributions, and wholesale drug warehouses; independent wholesale drug traders; and retail pharmacies conducting wholesale distributions. No person shall be subject to any state or local tax as a wholesale merchant by reason of this definition.

The words "drugs" and "devices" as used in Chapter 33 (§ 54.1-3300 et seq.) and in this chapter shall not include surgical or dental instruments, physical therapy equipment, X-ray apparatus, or glasses or lenses for the eyes.

The terms "pharmacist," "pharmacy," and "practice of pharmacy" as used in this chapter shall be defined as provided in Chapter 33 (§ 54.1-3300 et seq.) unless the context requires a different meaning.

§ 54.1-3406. Records confidential; disclosure of information about violations of federal law.

A. No agent of the Board or agent designated by the Superintendent of the Department of State Police having knowledge by virtue of his office of any prescriptions, papers, records, or stocks of drugs shall divulge such knowledge, except in connection with a criminal investigation authorized by the Attorney General or attorney for the Commonwealth or with a prosecution or proceeding in court or before a regulatory board or officer, to which investigation, prosecution or proceeding the person to whom such prescriptions, papers or records relate is a subject or party. This section shall not be construed to prohibit the Board president or his designee and the Director of the Department of Health Professions from discharging their duties as provided in this title.

B. Notwithstanding the provisions of § 54.1-2400.2, the Board shall have the authority to submit to the U.S. Secretary of Health and Human Services information resulting from an inspection or an investigation indicating that a compounding pharmacy or outsourcing facility may be in violation of federal law or regulations with the exception of compounding for office-based administration in accordance with §54.1-3410.2.

§ 54.1-3410.2. Compounding; pharmacists' authority to compound under certain conditions; labeling and record maintenance requirements.

A. A pharmacist may engage in compounding of drug products when the dispensing of such compounded products is (i) pursuant to valid prescriptions for specific patients and (ii) consistent with

the provisions of § 54.1-3303 relating to the issuance of prescriptions and the dispensing of drugs.

Pharmacists shall label all compounded drug products that are dispensed pursuant to a prescription in accordance with this chapter and the Board's regulations, and shall include on the labeling an appropriate beyond-use date as determined by the pharmacist in compliance with USP-NF standards for pharmacy compounding.

B. A pharmacist may also engage in compounding of drug products in anticipation of receipt of prescriptions based on a routine, regularly observed prescribing pattern.

Pharmacists shall label all products compounded prior to dispensing with (i) the name and strength of the compounded medication or a list of the active ingredients and strengths; (ii) the pharmacy's assigned control number that corresponds with the compounding record; (iii) an appropriate beyond-use date as determined by the pharmacist in compliance with USP-NF standards for pharmacy compounding; and (iv) the quantity.

C. In accordance with the conditions set forth in subsections A and B, pharmacists shall not distribute compounded drug products for subsequent distribution or sale to other persons or to commercial entities, including distribution to pharmacies or other entities under common ownership or control with the facility in which such compounding takes place; however, a pharmacist may distribute to a veterinarian in accordance with federal law.

Compounded products for companion animals, as defined in regulations promulgated by the Board of Veterinary Medicine, and distributed by a pharmacy to a veterinarian for further distribution or sale to his own patients shall be limited to drugs necessary to treat an emergent condition when timely access to a compounding pharmacy is not available as determined by the prescribing veterinarian.

A pharmacist may, however, deliver compounded products dispensed pursuant to valid prescriptions to alternate delivery locations pursuant to § 54.1-3420.2.

A pharmacist may also provide a reasonable amount of compounded products to practitioners of medicine, osteopathy, podiatry, or dentistry, or veterinary medicine to administer to their patients in the course of their professional practice, either personally or under their direct and immediate supervision, if there is a critical need to treat an emergency condition, or as allowed by federal law or regulations. A pharmacist may also provide compounded products to practitioners of veterinary medicine for office-based administration to their patients.

Pharmacists who provide compounded products for office-based administration for treatment of an emergency condition or as allowed by federal law or regulations shall label all compounded products distributed to practitioners other than veterinarians for administration to their patients with (i) the statement "For Administering in Prescriber Practice Location Only"; (ii) the name and strength of the compounded medication or list of the active ingredients and strengths; (iii) the facility's control number; (iv) an appropriate beyond-use date as determined by the pharmacist in compliance with USP-NF standards for pharmacy compounding; (v) the name and address of the pharmacy; and (vi) the quantity.

Pharmacists shall label all compounded products for companion animals, as defined in regulations promulgated by the Board of Veterinary Medicine, and distributed to a veterinarian for either further distribution or sale to his own patient or administration to his own patient with (a) the name and strength of the compounded medication or list of the active ingredients and strengths; (b) the facility's control number; (c) an appropriate beyond-use date as determined by the pharmacist in compliance with USP-NF standards for pharmacy compounding; (d) the name and address of the pharmacy; and (e) the quantity.

D. Pharmacists shall personally perform or personally supervise the compounding process, which shall include a final check for accuracy and conformity to the formula of the product being prepared, correct ingredients and calculations, accurate and precise measurements, appropriate conditions and procedures, and appearance of the final product.

E. Pharmacists shall ensure compliance with USP-NF standards for both sterile and non-sterile compounding.

F. Pharmacists may use bulk drug substances in compounding when such bulk drug substances:

1. Comply with the standards of an applicable United States Pharmacopoeia or National Formulary monograph, if such monograph exists, and the United States Pharmacopoeia chapter on pharmacy compounding; or are drug substances that are components of drugs approved by the FDA for use in the United States; or are otherwise approved by the FDA;

2. Are manufactured by an establishment that is registered by the FDA; or

3. Are distributed by a licensed wholesale distributor or registered nonresident wholesale distributor, or are distributed by a supplier otherwise approved by the FDA to distribute bulk drug substances if the pharmacist can establish purity and safety by reasonable means, such as lot analysis, manufacturer reputation, or reliability of the source.

G. Pharmacists may compound using ingredients that are not considered drug products in accordance with the USP-NF standards and guidance on pharmacy compounding.

H. Pharmacists shall not engage in the following:

1. The compounding for human use of a drug product that has been withdrawn or removed from the market by the FDA because such drug product or a component of such drug product has been found to be unsafe. However, this prohibition shall be limited to the scope of the FDA withdrawal;

2. The regular compounding or the compounding of inordinate amounts of any drug products that are essentially copies of commercially available drug products. However, this prohibition shall not include (i) the compounding of any commercially available product when there is a change in the product ordered by the prescriber for an individual patient, (ii) the compounding of a commercially manufactured drug only during times when the product is not available from the manufacturer or supplier, (iii) the compounding of a commercially manufactured drug whose manufacturer has notified the FDA that the drug is unavailable due to a current drug shortage, (iv) the compounding of a commercially manufactured drug when the prescriber has indicated in the oral or written prescription for an individual patient that there is an emergent need for a drug that is not readily available within the time medically necessary, or (v) the mixing of two or more commercially available products regardless of whether the end product is a commercially available product; or

3. The compounding of inordinate amounts of any preparation in cases in which there is no observed historical pattern of prescriptions and dispensing to support an expectation of receiving a valid prescription for the preparation. The compounding of an inordinate amount of a preparation in such cases shall constitute manufacturing of drugs.

I. Pharmacists shall maintain records of all compounded drug products as part of the prescription, formula record, formula book, or other log or record. Records may be maintained electronically, manually, in a combination of both, or by any other readily retrievable method.

1. In addition to other requirements for prescription records, records for products compounded pursuant to a prescription order for a single patient where only manufacturers' finished products are used as components shall include the name and quantity of all components, the date of compounding and dispensing, the prescription number or other identifier of the prescription order, the total quantity of finished product, the signature or initials of the pharmacist or pharmacy technician performing the compounding, and the signature or initials of the pharmacist responsible for supervising the pharmacy technician and verifying the accuracy and integrity of compounded products.

2. In addition to the requirements of subdivision I 1, records for products compounded in bulk or batch in advance of dispensing or when bulk drug substances are used shall include: the generic name and the name of the manufacturer of each component or the brand name of each component; the manufacturer's lot number and expiration date for each component or when the original manufacturer's lot number and expiration date are unknown, the source of acquisition of the component; the assigned lot number if subdivided, the unit or package size and the number of units or packages prepared; and the beyond-use date. The criteria for establishing the beyond-use date shall be available for inspection by the Board.

3. A complete compounding formula listing all procedures, necessary equipment, necessary environmental considerations, and other factors in detail shall be maintained where such instructions are necessary to replicate a compounded product or where the compounding is difficult or complex and must be done by a certain process in order to ensure the integrity of the finished product.

4. A formal written quality assurance plan shall be maintained that describes specific monitoring and evaluation of compounding activities in accordance with USP-NF standards. Records shall be maintained showing compliance with monitoring and evaluation requirements of the plan to include training and initial and periodic competence assessment of personnel involved in compounding, monitoring of environmental controls and equipment calibration, and any end-product testing, if applicable.

J. Practitioners who may lawfully compound drugs for administering or dispensing to their own patients pursuant to §§ 54.1-3301, 54.1-3304, and 54.1-3304.1 shall comply with all provisions of this section and the relevant Board regulations.

K. Every pharmacist-in-charge or owner of a permitted pharmacy or a registered nonresident pharmacy engaging in sterile compounding shall notify the Board of its intention to dispense or otherwise deliver a sterile compounded drug product into the Commonwealth. Upon renewal of its permit or registration, a pharmacy or nonresident pharmacy shall notify the Board of its intention to continue dispensing or otherwise delivering sterile compounded drug products into the Commonwealth. Failure to provide notification to the Board shall constitute a violation of Chapter 33 (§ 54.1-3300 et seq.) or Chapter 34 (§ 54.1-3400 et seq.). The Board shall maintain this information in a manner that will allow the production of a list identifying all such sterile compounding pharmacies.

§ 54.1-3434.05. Permit to act as an outsourcing facility.

A. No person shall act as an outsourcing facility without first obtaining a permit from the Board.

B. Applications for a permit to act as an outsourcing facility shall be made on a form provided by the Board and signed by a pharmacist who will be in full and actual charge of the outsourcing facility and who will be fully engaged in the compounding performed at the location designated on the

428 application. Such application shall be accompanied by a fee determined by the Board in regulation. All
429 permits shall expire annually on a date determined by the Board in regulation. No permit shall be
430 issued or renewed for an outsourcing facility unless the facility can demonstrate compliance with all
431 applicable federal and state laws and regulations governing outsourcing facilities.

432 C. As a prerequisite to obtaining or renewing a permit from the Board, the outsourcing facility shall
433 (i) register as an outsourcing facility with the U.S. Secretary of Health and Human Services in
434 accordance with 21 U.S.C. § 353b and (ii) submit a copy of a current inspection report resulting from
435 an inspection conducted by the U.S. Food and Drug Administration that indicates compliance with the
436 requirements of state and federal law and regulations, including all applicable guidance documents and
437 Current Good Manufacturing Practices published by the U.S. Food and Drug Administration.

438 The inspection report required pursuant to clause (ii) shall be deemed current for the purposes of
439 this section if the inspection was conducted (a) no more than one year prior to the date of submission
440 of an application for a permit to the Board or (b) no more than two years prior to the date of
441 submission of an application for renewal of a permit to the Board. However, if the outsourcing facility
442 has not been inspected by the U.S. Food and Drug Administration within the required period, the Board
443 may accept an inspection report or other documentation from another entity that is satisfactory to the
444 Board, or the Board may cause an inspection to be conducted by its duly authorized agent and may
445 charge an inspection fee in an amount sufficient to cover the costs of the inspection.

446 D. Every outsourcing facility shall compound in compliance with the requirements of state and
447 federal law and regulations except §54.1-3410.2, to include all applicable guidance documents and
448 Current Good Manufacturing Practices published by the U.S. Food and Drug Administration.

449 E. An outsourcing facility shall not engage in compounding of drug products to be dispensed
450 pursuant to a valid prescription for a specific patient without first obtaining a permit to operate a
451 pharmacy.

452 **§ 54.1-3434.4. Prohibited acts.**

453 A. It is unlawful for any person or entity which is not registered under this article to (i) conduct the
454 business of shipping, mailing, or otherwise delivering Schedule II through VI controlled substances into
455 Virginia or (ii) advertise the availability for purchase of any Schedule II through VI controlled
456 substances by any citizen of the Commonwealth. Further, it shall be unlawful for any person who is a
457 resident of Virginia to advertise the pharmacy services of a nonresident pharmacy ~~which~~ or
458 ~~compounding services of an outsourcing facility that~~ has not registered with the Board, with the
459 knowledge that the advertisement will or is likely to induce members of the public in the
460 Commonwealth to use the pharmacy ~~or outsourcing facility~~ to obtain controlled substances.

461 B. Any controlled substance that is ordered or shipped in violation of any provision of this chapter,
462 shall be considered as contraband and may be seized by any law-enforcement officer or any agent of the
463 Board of Pharmacy.

464 **§ 54.1-3434.5. Nonresident outsourcing facilities to register with the Board.**

465 A. Any outsourcing facility located outside the Commonwealth that ships, mails, or delivers in any
466 manner Schedule II through VI drugs or devices into the Commonwealth shall be considered a
467 nonresident outsourcing facility and shall be registered with the Board.

468 B. Applications for registration to act as a non-resident outsourcing facility shall be made on a form
469 provided by the Board and signed by a pharmacist who is licensed as a pharmacist in Virginia and who
470 is in full and actual charge of the outsourcing facility, is fully engaged in the compounding performed
471 at the location stated on the application, and is fully responsible for the outsourcing facility's
472 compliance with state and federal law and regulations. Such application shall be accompanied by a fee
473 determined by the Board in regulation. All registrations shall expire annually on a date determined by
474 the Board in regulation.

475 C. As a prerequisite to registering or renewing a registration with the Board, the outsourcing facility
476 shall (i) register as an outsourcing facility with the U.S. Secretary of Health and Human Services in
477 accordance with 21 U.S.C. § 353b and (ii) submit a copy of a current inspection report resulting from
478 an inspection conducted by the U.S. Food and Drug Administration that indicates compliance with the
479 requirements of state and federal law and regulations, including all applicable guidance documents and
480 Current Good Manufacturing Practices published by the U.S. Food and Drug Administration.

481 The inspection report required pursuant to clause (ii) shall be deemed current for the purposes of
482 this section if the inspection was conducted (a) no more than one year prior to the date of submission
483 of an application for registration with the Board or (b) no more than two years prior to the date of
484 submission of an application for renewal of a registration with the Board. However, if the outsourcing
485 facility has not been inspected by the U.S. Food and Drug Administration within the required period,
486 the Board may accept an inspection report or other documentation from another entity that is
487 satisfactory to the Board, or the Board may cause an inspection to be conducted by its duly authorized
488 agent and may charge an inspection fee in an amount sufficient to cover the costs of the inspection.

489 D. A nonresident outsourcing facility shall not engage in compounding of drug products to be

490 *dispensed pursuant to a valid prescription for a specific patient without first obtaining a registration to*
491 *operate a nonresident pharmacy. The nonresident pharmacy shall comply with all state and federal*
492 *laws, regulations, and requirements except § 54.1-3410.2.*
493 **2. That the Board of Pharmacy shall promulgate regulations to implement the provisions of this**
494 **act to be effective within 280 days of its enactment.**

INTRODUCED

HB1737